A new class of test, Registered with the mhra

It is estimated that one in two people will be diagnosed with some form of cancer within their lifetime (1). 70% of cancer deaths occur from cancers without available screening (2).

Enlighten® is a first-in-class Multi-Cancer Early Detection test that measures the host response to tumour development, strongest in early-stage cancers, using an affordable, fluorescence-kit-based microplate reader assay. 

Our biorthogonal chemistry enables direct measurement of the host response from crude patient plasma, eliminating complex sample preparation. Enlighten® is built for real-word adoption.

Our unique technology allows whole blood samples to remain at room temperature in

common and inexpensive standard EDTA collection tubes for up to 48 hours before processing into plasma. This enables accessible sample collection in distributed settings (pharmacies and mobile vans).

MODERNISED is evaluating Enlighten® in Breast, Colorectal, Prostate, Pancreatic, Lung, Melanoma, Oesophageal, Ovarian, Bladder, and Renal cancer.  

MODERNISED: A prospective observational study to generate evidence on the performance characteristics of Enlighten®, and to design a NHS programme for the use of the test, providing acceptable, effective, equitable, and cost-effective screening.